IL1RL2 and neoplasm: In line with our findings that IL-36 agonists drive proliferation of tumour cells, IHC for Ki-67 as a marker of cellular proliferation revealed significantly decreased Ki-67 positive cells in both IL-36Ra-treated groups in comparison to both the control group and IL-36R agonist cocktail-treated groups, with representative images shown in Fig. 5B.